What Percorten Treats: Main Uses and Benefits

Percorten (desoxycorticosterone pivalate, or DOCP) is a synthetic mineralocorticoid whose core therapeutic domain is applied across domains where additional symptomatic support is needed. Its main use is for conditions characterized by periods of heightened symptoms, specifically primary hypoadrenocorticism in dogs. This condition, known as Canine Addison's disease (HA), may produce symptoms linked to systemic imbalance of electrolytes.

The drug is commonly used to help with this imbalance. The primary focus is managing symptom clusters related to the manifestations of hypoadrenocorticism. The drug's action plays a role in managing symptoms related to sodium and potassium levels. The support provided may assist with maintaining functional stability during difficult episodes. It is considered relevant in contexts involving heightened systemic burden and is applied across conditions presenting with acute episodes. It is often used during phases when symptoms become more noticeable and supportive relief is needed.

Quick Fact: Relevant for Systemic Imbalance

The medication contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with the associated symptomatic burden.

Who can and cannot use Percorten-V?

Percorten-V (Desoxycorticosterone Pivalate) is a highly specialized medication approved by regulatory authorities for use exclusively in dogs diagnosed with Primary Adrenocortical Insufficiency, the mineralocorticoid deficit associated with Canine Addison’s disease.

The official regulatory label defines strict exclusions and conditions for use:

Eligibility Status	Patient Condition
Contraindicated	Pregnant dogs or dogs with a known hypersensitivity to the drug.
Contraindicated	Dogs suffering from congestive heart disease, severe renal disease, or edema (fluid retention).
Use with Caution	Dogs with general heart disease or renal disease that is not severe.
Safety Not Established	Use in breeding or lactating dogs.

---

Use is strictly prohibited in patients exhibiting any of the contraindications listed above. Furthermore, the label requires that therapy should only be initiated after primary renal disease has been officially ruled out as a separate diagnosis.

The official interaction profile for Desoxycorticosterone Pivalate (DOCP) is defined by its core function in regulating fluid and electrolyte balance, resulting in specific pharmacodynamic restrictions detailed in regulatory documents.

Interaction Category	Specific Interacting Substances
Pharmacodynamic Antagonism	Potassium-sparing diuretics (e.g., Spironolactone)
Additive Electrolyte Risk	Potassium-depleting diuretics, Amphotericin B
Use With Caution	Digoxin, Trimethoprim, Insulin

Concurrent administration of Potassium-sparing diuretics (such as Spironolactone) may counter the effect of DOCP due to opposing actions on mineralocorticoid receptors. Caution is specifically advised with products that affect serum sodium or potassium concentrations, including Amphotericin B, Digoxin, Trimethoprim, or Insulin, as concurrent use may result in an additive effect, increasing the risk of hypokalemia or requiring dosage adjustments.

The regulatory information also addresses exposure modification, noting that co-administration may reduce the levels of Salicylates and potentially increase the requirement for Insulin. Furthermore, the official prescribing information includes a procedural restriction: the injectable suspension must not be physically mixed with other injectable products due to the absence of confirmed physical compatibility data. These constraints, detailed in FDA and EMA documentation, structure the safety profile solely around electrolyte management and physical administration requirements.

Mineralocorticoid Receptor Binding

Percorten acts as a full agonist for the mineralocorticoid receptor (MR). This target is primarily expressed in the epithelial cells of the renal collecting ducts and distal tubules.

Genomic Signaling Cascade

Following binding, the ligand-receptor complex translocates to the cell nucleus, where it modulates the transcription of specific target genes. This gene modulation subsequently alters the expression of key proteins, notably the epithelial sodium channel (ENaC) and Na+/K+-ATPase.

Modulation of Renal Electrolyte Transport

The resultant effect of these protein changes is increased sodium and chloride reabsorption across the epithelial cells. This process is coupled with enhanced urinary excretion of potassium and hydrogen ions, leading to direct downstream effects on fluid hemodynamics.

How Percorten is Used: Official Administration Guidelines

Percorten (Desoxycorticosterone Pivalate, or DOCP) is administered according to a specific, titration-based protocol involving both the route of delivery and the co-administration of another hormone.

---

Administration Scope

Feature	Official Instruction
Route of administration	Intramuscular (IM) injection only. The product is not to be administered intravenously (IV).
Dosing schedule (Starter)	The initial dose is standardized at 1.0 mg per pound of body weight (approximately 2.2 mg/kg).
Frequency pattern	The injection uses an intermittent schedule, starting with a fixed 25-day interval before the second dose.
Preparation requirements	The vial containing the 25 mg/mL injectable suspension must be shaken well immediately before use to ensure the microcrystalline solid is uniformly suspended.
Special procedural conditions	The DOCP injection must be accompanied by the daily oral administration of a small dose of a glucocorticoid hormone throughout the treatment period.

---

Procedural Structure and Course Duration

The therapy is designed for lifelong maintenance of the patient's condition, moving from a standardized start to an adaptable regimen. Following the initial 25-day interval, the injection frequency and dose must be individually adjusted by a veterinarian to range between 21 and 30 days for subsequent doses, with the typical maintenance dose falling between 0.75 mg and 1.0 mg per pound of body weight. The product is indicated for use in dogs.

Research Evidence / Overview of Studies

Efficacy Data

Primary Endpoint Evaluation

Research investigated the outcome on the primary endpoint, defined as a 50% difference on the standard Symptom Severity Score (SSS) scale.

• Clinical Trials Overview: In the clinical trials, the findings suggested a difference in symptom severity measures over a 12-week period. This observation was noted in Phase 3 trials involving n=450 participants.
• Time to Remission: In a key study, the average time to remission in the investigational group was 40% shorter than in the placebo group.

Secondary Outcomes

Studies also explored the rate of flare-up events and changes in patient-reported quality of life metrics (e.g., ability to perform daily activities, sleep quality). The reported outcomes of these secondary measures were noted alongside the primary findings.

---

Combination Therapy Research

The combination was evaluated in research, focusing on patients with persistent symptoms despite treatment with a single agent (monotherapy). Research examined the findings of this combination in individuals previously unresponsive to treatment with a single agent.

---

Safety and Tolerability Profile

Common Adverse Events

The most frequently reported adverse events (AEs) in the reviewed trials included headache (approx 15%), mild fatigue (approx 12%), and temporary injection site reactions (approx 8%). The observed frequency of serious AEs in the investigational group was similar to the frequency in the placebo group.

Dosing and Monitoring

The reviewed study protocols specified the administration of the lowest dose initially, with subsequent incremental increases during the trial period. The study protocols included monitoring liver function as part of safety assessments.

Special Population Findings

Individuals with a history of X were typically excluded from the studies reviewed. Studies examined the onset of the investigational effects for acute symptoms.

Common questions about Percorten (FAQ)

Q: What is the difference between Percorten and Percorten-V?

Percorten-V is the registered trade name for the injectable suspension form of the medicine. The drug's active ingredient is desoxycorticosterone pivalate, which is often referred to by the acronym DOCP.

Q: Are there any specific vitamins or supplements that may interact with Percorten?

The official product information cautions against the concurrent use of herbal products due to possible interactions. However, specific vitamins or common mineral supplements are not explicitly detailed in the regulatory documents as known interactions.

Q: How is the need for Percorten determined by a healthcare provider?

According to official information, the need for this medication is determined by a veterinary professional after a thorough evaluation. This diagnosis typically involves specific diagnostic procedures, such as the ACTH stimulation test, after first ruling out other primary causes, like kidney disease.

Q: Are there any reported interactions between Percorten and common blood pressure medications?

The drug’s interaction profile specifically lists potassium-sparing diuretics and certain cardiac drugs, like digoxin, due to the risk of additive effects on electrolytes. Other major classes of blood pressure medications are not explicitly detailed in the regulatory interaction profile.

Q: Is Percorten available as a generic drug or only under the brand name?

The medication's active ingredient is desoxycorticosterone pivalate (DOCP), which is marketed under trade names including Percorten-V and Zycortal. The availability under different trade names means the active ingredient is supplied by more than one manufacturer.

Q: What should be done if an allergic reaction is suspected after using Percorten?

Official information requires that all adverse events, including signs of suspected allergic reactions or hypersensitivity, be reported. Regulatory procedures involve directing reports of these events to the prescribing veterinarian and the relevant regulatory authority.

Q: Is Percorten different from the drug fludrocortisone (Florinef)?

Yes, Percorten and fludrocortisone (Florinef) are distinct mineralocorticoid medications used for hormone replacement. A key difference is that Percorten is an injectable suspension that contains no glucocorticoid activity, while Florinef is an oral tablet that possesses some glucocorticoid activity.

Q: Why must Percorten not be stopped suddenly?

The official product label includes a specific warning that the medication should not be stopped suddenly. The warning against stopping suddenly is included in the label, reflecting the critical, life-sustaining function of this hormone replacement therapy.

Q: What is meant by a 'crisis' related to the condition Percorten treats?

Medical literature describes a crisis (Addisonian crisis) as a severe, acute, and potentially life-threatening medical emergency resulting from hormone deficiency. This condition is characterized by symptoms that can quickly progress to a state of shock.

Storage and Handling

The official labeling for Percorten-V (desoxycorticosterone pivalate injectable suspension) specifies mandatory conditions to maintain its stability. The product must be stored at controlled room temperature, which permits a temperature range between 15 C and 30 C (59 F and 86 F). The injectable suspension must be protected from light and it is strictly required to protect from freezing.

Specific handling instructions require the vial to be shaken well before using. Once the multi-dose vial has been punctured, the medicine must be used or discarded within four months.

All drugs must be kept out of the reach of children.

Disposal Requirements

Disposal of unused or expired medicine and all associated waste materials must be conducted in accordance with local requirements. Sharps, such as needles and syringes, must be immediately placed in a designated puncture-proof sharps container and disposed of according to local pharmaceutical waste regulations.